Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.65M | 1.70M | 1.57M | 1.62M | 1.26M |
| Depreciation & Amortization | 200.00 | 300.00 | 400.00 | 400.00 | 400.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.15M | 2.52M | 2.39M | 2.48M | 2.55M |
| Operating Income | -2.15M | -2.52M | -2.39M | -2.48M | -2.55M |
| Income Before Tax | -3.88M | -4.19M | -4.14M | -3.13M | -3.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.88 | -4.19 | -4.14 | -3.13 | -3.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.88M | -4.19M | -4.14M | -3.13M | -3.18M |
| EBIT | -2.15M | -2.52M | -2.39M | -2.48M | -2.55M |
| EBITDA | -2.15M | -2.52M | -2.39M | -2.48M | -2.55M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.64B | 1.58B | 1.52B | 1.42B | 1.37B |
| Average Diluted Shares Outstanding | 1.64B | 1.58B | 1.52B | 1.42B | 1.37B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |